Curanex Pharmaceuticals (CURX) Assets Average (2025 - 2026)
Curanex Pharmaceuticals' (CURX) quarterly Assets Average came in at $8.3 million in Q2 2026, up 1176.07% on a YoY basis from $652554.5 in Q2 2025, and down 36.09% quarter-over-quarter from $13.0 million in Q4 2025.
Powered by 
Analysis
Curanex Pharmaceuticals (CURX) Assets Average (2025 - 2026) Analysis & Trends
Curanex Pharmaceuticals (CURX) has reported Assets Average for 2 consecutive years, with $8.3 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Assets Average rose 1176.07% year-over-year to $8.3 million; the trailing twelve-month figure through Jun 2026 stood at $8.3 million (up 1176.07% YoY), and the FY2025 full-year result was $6.0 million, changed N/A from the prior year.
- Assets Average eased to $8.3 million in Q2 2026 per CURX's latest filing, from $13.0 million in the prior quarter.
- Across five years, Assets Average topped out at $13.0 million in Q4 2025 and bottomed at $652554.5 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 120.28 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 204.57 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 149.95 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 3.29 Bn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 7.61 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 6.97 Bn |
| 10 | Curanex Pharmaceuticals | 5.97 Mn | 3.03 Mn | - | 8.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.33 Mn |
| Dec 31, 2025 | 13.03 Mn |
| Sep 30, 2025 | 7.63 Mn |
| Jun 30, 2025 | 652,554.50 |